Quince Therapeutics shares rise 11.99% intraday after announcing management's participation in December investor events and receiving "Moderate Buy" ratings from eight analysts with $8.00 target price.

miércoles, 26 de noviembre de 2025, 10:01 am ET1 min de lectura
QNCX--
Quince Therapeutics surged 11.99% intraday trading, with the company announcing senior management's participation in a December investor event, including the Piper Sandler healthcare conference, and eight analysts covering the stock with an average "Moderate Buy" rating and $8.00 price target.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios